The need for thorough phase II studies in medicines development for Alzheimer’s disease

An important factor in the universal failure in phase III trials in mild to moderate Alzheimer’s disease in the past decade is the lack of phase II clinical data prior to entering phase III, with common reliance on biomarker results alone. Conduction of two learn-confirm cycles according to the Shei...

Descripción completa

Detalles Bibliográficos
Autores principales: Gray, Julian A., Fleet, David, Winblad, Bengt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620743/
https://www.ncbi.nlm.nih.gov/pubmed/26503107
http://dx.doi.org/10.1186/s13195-015-0153-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620743/
https://www.ncbi.nlm.nih.gov/pubmed/26503107
http://dx.doi.org/10.1186/s13195-015-0153-y

Ejemplares similares